Based on MYCN amplification status, age at diagnosis, INSS stage, histopathology, and tumor cell ploidy, NB patients are stratified into low-, intermediate-, and high-risk groups according to the 2007 COG risk system (30, 31). This evidence concerns the gene MYCN and neoplasm.